U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Obesity and Metabolism Research: Davis, CA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Laboratories
                        Bennett Group
                                    Huang Group
                                    Keim Group
                                    Laugero Group
                                    Newman GroupSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Pacific West Area Davis, California Western Human Nutrition Research Center Obesity and Metabolism Research Research Publications at this Location





- ARS National Programs
- Search for a scientific manuscript
- Search for a research project
- ARS Software
- Programs and Projects
- Collaborations
- Subjects of Investigation
- Publications

Title:   Author  item
                                            OLEARCZYK, JEFFREY - MED. COLLEGE OF GEORGIAitem
                                            QUIGLEY, JEFFREY - MED. COLLEGE OF GEORGIAitem
                                            MITCHELL, BRADFORD - MED. COLLEGE OF GEORGIAitem
                                            YAMAMOTO, TATSUO - HAMAMATSU UNIV. SCH.MED.item
                                            KIM, IN-HAE - UCD,DEPT. OF ENTOMOL.item
                                            Newman, Johnitem
                                            LURIA, AYALA - UCD, DEPT. OF ENTOMOL.item
                                            HAMMOCK, BRUCE - UCD, DEPT. OF ENTOMOL.item
                                            IMIG, JOHN - MED. COLLEGE OF GEORGIA
  Submitted to: Trade Journal Publication
                                    Publication Type: Peer Reviewed Journal
                                    Publication Acceptance Date: 1/20/2009
                                    Publication  Date: 1/1/2010
                                    Citation: Olearczyk, J.J., Quigley, J.E., Mitchell, B.C., Yamamoto, T., Kim, I., Newman, J.W., Luria, A., Hammock, B.D., Imig, J.D. 2010. ADMINISTRATION OF A SUBSTITUTED ADAMANTLY-UREA INHIBITOR OF THE SOLUBLE EPOXIDE HYDROLASE PROTECTS THE KIDNEY FROM DAMAGE IN HYPERTENSIVE GOTO-KAKIZAKI RATS. Trade Journal Publication. 10.1042/CS20080039.Interpretive Summary: Hypertension and type II diabetes are co-morbid diseases that lead to the development of renal damage and recent reports suggest that soluble epoxide hydrolase inhibitors provide protection from renal damage. Based on these reports, we hypothesized that the soluble epoxide hydrolase inhibitors could also prevent renal damage associated with hypertension and diabetes. To this end, we induced hypertension in spontaneously diabetic Goto-Kakizaki rats (GK) using angiotensin II and a high salt diet. The hypertensive rats were then treated with either a soluble epoxide hydrolase inhibitor, or its vehicle, for two weeks in the drinking water.  While the sEH inhibitor did not prevent the rise in blood pressure or plasma glucose, it was able to reduce the associated urinary albumin excretion. Moreover, histology showed this treatment reduced the glomerular and tubular damage characteristic of nephropathy seen in this animal model of kidney disease. This reduction was also associated with a reduced level of macrophage infiltration into these tissues, and reduced kidney expression and excretion of monocyte chemoattractant protein 1. Taken together, these data provide evidence that sEH inhibition can slow the progression of nephropathy associated with hypertension and type II diabetes
                                Technical Abstract: Hypertension and type II diabetes are co-morbid diseases that lead to the development of nephropathy. Soluble epoxide hydrolase (sEH) inhibitors are reported to provide protection from renal injury.  We hypothesized that the sEH inhibitor 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) protects the kidney from the development of nephropathy associated with hypertension and type II diabetes. Hypertension was induced in spontaneously diabetic Goto-Kakizaki rats (GK) using angiotensin II and a high salt diet. Hypertensive GK rats were treated for two weeks with either AUDA or its vehicle added to drinking water. Mean arterial pressure increased from 118 ± 2 mmHg to 182 ± 20 and 187 ± 6 mmHg for vehicle and AUDA treated hypertensive GK rats, respectively. AUDA treatment did not alter blood glucose. Hypertension in GK rats resulted in a 17-fold increase in urinary albumin excretion which was decreased with AUDA treatment. Renal histological evaluation determined that AUDA treatment decreased glomerular and tubular damage characteristic of nephropathy. In addition, AUDA treatment attenuated macrophage infiltration and inhibited urinary excretion of monocyte chemoattractant protein 1 (MCP-1) and kidney cortex MCP-1 gene expression. Taken together, these data provide evidence that sEH inhibition with AUDA attenuates the progression of nephropathy associated with hypertension and type II diabetes.


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov